537 results on '"De Meerleer, G."'
Search Results
2. Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial
3. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial
4. Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer
5. Natural history of pN1 prostate cancer after radical prostatectomy: Competing risk analysis from a large multi-institutional series
6. Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: A subanalysis of the ARNEO trial
7. Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer – a monocentric positive lymph node mapping study
8. Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer
9. [18F]PSMA-1007 PET/CT in the detection of neoplastic lumbosacral plexopathy as an emerging and underestimated spread of prostate cancer
10. PET–CT for staging patients with muscle invasive bladder cancer: is it more than just a fancy tool?
11. Salvage Radiotherapy for Prostate Cancer
12. Progression-Directed Therapy in Oligoprogressive Castration-Refractory Prostate Cancer: Results of the Prospective Single-Arm Phase II MEDCARE Trial
13. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
14. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.
15. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences
16. High-risk prostate cancer
17. 174TiP SPARKLE: A new spark in treating oligorecurrent prostate cancer: Adding systemic treatment to stereotactic body radiotherapy or metastasectomy: Key to long-lasting event-free survival?
18. Long-Term Outcomes and Genetic Predictors of Response to Metastasis Directed Therapy vs. Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials
19. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics
20. Toxicity profile of immediate post-prostatectomy radiation therapy: results from a large multi-institutional series
21. 1381P A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer
22. PO-1406 Hematological toxicity in pN1 prostate cancer patients treated with extended field irradiation
23. PO-1495 Protons versus photons for oligometastatic prostate cancer: a planning comparison
24. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
25. Predicting patient-reported symptom clusters in prostate cancer patients: A machine learning approach
26. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: The key role of PSA kinetics
27. PSA doubling time as predictor of relapse after early salvage radiation therapy: When should imaging be used to select patients who might not benefit from early local treatments?
28. The Impact of Clinical Factors on the Development of Late Radiation Toxicity: Results from the Medical Research Council RT01 Trial (ISRCTN47772397)
29. A Comparison of the Acute Toxicity Profile between Two-dimensional and Three-dimensional Image-guided Radiotherapy for Postoperative Prostate Cancer
30. Metastasis-Directed Therapy for Oligoprogressive Castration-Resistant Prostate Cancer ― Preliminary Results of the Prospective, Single-Arm MEDCARE Trial
31. Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei
32. Imaging treated prostate cancer
33. The key role of PSA doubling time in patients treatedwith salvage radiation therapy after radical prostatectomy: implications for the extent of radiation and the concomitant use of hormonal therapy
34. Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treatedwith post-prostatectomy radiation therapy: results from a large, multi-institutional study
35. Very long term outcomes, time patterns of recurrence and other-cause mortality in patients treated with salvage radiation therapy for recurrent prostate cancer after radical prostatectomy: implications for risk tailored follow-up strategies
36. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 prostate cancer? Results form a large multi-institutional series
37. There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy. a retrospective, multi-centre analyses on oncological and toxicity outcomes
38. PD-0850 Adjuvant radiotherapy after cystectomy for patients with bladder cancer: a phase II trial.
39. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 Prostate Cancer? Results form a large Multi-Institutional series
40. The key role of PSA doubling time in patients treated with salvage radiation therapy after radical prostatectomy: Implications for the extent of radiation and the concomitant use of hormonal therapy
41. Very long-term outcomes, time patterns of recurrence and other-cause mortality in patients treated with salvage radiation therapy for recurrent prostate cancer after radical prostatectomy: Implications for risk tailored follow-up strategies
42. Comparison of salvage radiation therapy delivered for PSA persistence versus PSA relapse after radical prostatectomy: How is the outcome changing?
43. Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treated with post-prostatectomy radiation therapy: Results from a large, multi-institutional study
44. A novel prognostic model for patients undergoing salvage radiotherapy for biochemical recurrence after radical prostatectomy
45. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0).
46. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.
47. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
48. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
49. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.
50. Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer: Toxicity, tumour response and outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.